A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Retired Oak Ridge, Tennessee, physician notes the downside of a class of drugs − GLP-1s − first approved for treating ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...

In response to rising demand for weight loss medications, WeightWatchers has launched a low-cost alternative to ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

In addition to availability, the cost of weight loss drugs like Wegovy and Zepbound is a major barrier preventing many ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.